Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Subscribe To Our Newsletter & Stay Updated